Interim assessment of prospective phase Ⅱ trial evaluating efficacy of intensity-modulated radiotherapy with concurrent capecitabine for stage Ⅱ / Ⅲ gastric cancer after radical surgery

任骅,王鑫,房辉,李宁,金晶,刘跃平,王维虎,王淑莲,宋永文

DOI: https://doi.org/10.3760/cma.j.issn.1004-4221.2014.02.006

2014-01-01

Abstract:Objective To evaluate the preliminary efficacy and acute toxicities of intensity-modulated radiotherapy (IMRT) with concurrent capecitabine for stage Ⅱ/Ⅲ gastric cancer (AJCC 7th)after radical surgery and to decide whether to continue phase Ⅱ trial.Methods From 2009 to 2011,35 patients with gastric cancer (10 stage Ⅱ patients and 25 stage Ⅲ patients) were included in prospective phase Ⅱ trial to receive chemoradiotherapy.In radiotherapy,the patients received IMRT to the anastomosis,tumor bed,and regional lymph nodes at a dose of 45 Gy/25 fractions.In concurrent chemotherapy,the patients received capecitabine at 1 600 mg/m2 in two divided doses per day for 5 weeks; in adjuvant chemotherapy,the patients received fluorouracil or capecitabine ± oxaliplatin (4-8 cycles).The Kaplan-Meier method was used to calculate survival rates,and the log-rank test was used for univariate prognostic analysis.A disease-free survival (DFS) of 52.9％ was used as the lower limit for continuing study.Results With a median follow-up of 21 months,the follow-up rate was 94％.Radiotherapy was not completed in 3 patients.The 2-year DFS and overall survival (OS) were 70％ and 86％,respectively.The incidence rates of grade 3 acute gastrointestinal,hematologic,and overall toxicities were 11％,11％,and 26％,respectively.The prognostic analysis showed that signet-ring cell carcinoma and positive lymph node ratio were adverse prognostic factors for DFS,and advanced T stage (T4) was the adverse prognostic factor for OS.Conclusions The 2-year DFS was greater than 52.9％ among all patients with gastric cancer who received IMRT with concurrent capecitabine after radical surgery,and the toxicities were tolerable.Thus,phase Ⅱ trial could be continued.